Sponsorship Opportunities

Do you want to advertise with RPG?

Here is the current sponsorship prospectus.

Sponsorship Prospectus (pdf)

Please contact renaldietitians@eatright.org for more information.

Thank you to our current supporters:

Despite treatment with a phosphate binder, are your adult dialysis patients’ serum phosphorus levels above goal or fluctuating in and out of target range? Now is the time for a different approach with XPHOZAH® (tenapanor).

XPHOZAH is not a phosphate binder. XPHOZAH is the first and only phosphate absorption inhibitor (PAI) specifically indicated for adult patients on dialysis to reduce serum phosphorus as add on therapy when a phosphate binder does not work well or when patients are intolerant to any dose of a phosphate binder. XPHOZAH works differently than phosphate binders by blocking phosphorus absorption via the paracellular pathway. XPHOZAH is dosed as one 30 mg pill twice a day, before the first and last meals.

Act now! Talk with your patients’ prescribers. Consider adding XPHOZAH to help reduce serum phosphorus levels with the goal of getting patients to goal.

To learn more about XPHOZAH, access downloadable renal dietitian specific resources to help identify patients who may be candidates for XPHOZAH, find information about patient access and counseling, and hear from our partners in the renal community, please visit our RD Engage hub on XPHOZAH-hcp.com.

INDICATION

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

· Pediatric patients under 6 years of age
· Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

ardelyx.com

Disclosure for CO/CT Prescribers

Sponsorship Acknowledgment and Independence Statement

The Renal DPG (RPG) is grateful for the generous support of our sponsors. However, sponsorship does not imply an endorsement of sponsors products, services, or business practices. The views and opinions of our sponsors are their own and do not necessarily reflect those of RPG and the Academy. Our nonprofit remains committed to its mission and values while fostering partnerships that help advance our goals.